A Dedicated Outpatient Clinic for Leading-Edge Amyloidosis Care

As a nationally recognized Center of Excellence in the treatment of amyloidosis, City of Hope® is dedicated to providing patients access to innovative diagnostic and treatment options that are on the cutting edge of care. Our multidisciplinary team of amyloidosis experts includes hematologists, cardiologists, neurologist, and nephrologist , among others, working together to diagnose, treat and conduct research into light chain amyloidosis (AL), transthyretin amyloidosis (ATTR), and other subtypes of the disease.

City of Hope is a founding member of the National Comprehensive Cancer Network and named by U.S. News & World Report 2025-26 rankings as a Top 10 “Best Hospital” for the fourth consecutive year. We have consistently been named a “high performing” center for the treatment of multiple myeloma and other hematologic malignancies. As a world-renowned research institution, City of Hope also participates in many collaborative studies designed to help build a stronger standard of care for amyloidosis patients across the country and around the world.

If you refer an amyloidosis patient to City of Hope, they will be treated with compassion and expertise by a multidisciplinary clinical team of experts.

Some of the benefits of receiving treatment at City of Hope include:

• A nationally recognized hematologic malignancy program that brings together expert clinicians and scientists with extensive experience in diagnosis and treatment.
• Our dedicated outpatient amyloidosis program, which offers comprehensive care for all forms of amyloidosis and a wide range of treatment options, including tissue banking, advanced imaging, genetics, immune effector cell therapies and stem cell transplantation as well as clinical trials.
• Expertise in the treatment and management of light-chain amyloidosis , which may develop due to an otherwise low-burden blood cell abnormality and also affects up to 15% of patients with multiple myeloma
• Access to specialists in cardiac amyloidosis, a condition with a 15% prevalence in patients with aortic valve stenosis or heart failure with preserved ejection fraction
• Expertise in the diagnosis and management of ATTR
• Access to City of Hope’s portfolio of clinical trials for eligible patients
• Seamless coordination of care between cardiologists, hematologists and other amyloid experts

Learn more about how City of Hope can help your patients

Refer your patients to City of Hope’s advanced amyloidosis clinical trials and help drive progress in care.